LungLife AI, Inc (DI) - Overview

LungLife is a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence ("AI"). Lung cancer is one of the most lethal cancers, accounting for nearly a quarter of all cancer-related deaths in the US, and its global incidence has increased by 37 per cent. from 2007-2017. The Company's diagnostic solutions are designed to make significant improvements in the early detection of lung cancer.

Registrars:

Key Personnel

CEO: Paul Carmelo Pagano
Non-Executive Director: Sara Barrington
Non-Executive Chairman: Gordon Roy Davis
Senior Independent Non-Executive Director: Andrew Norman Boteler
Chief Finance Officer: David Mark Anderson

Contact Details

Address: 850 New Burton Road, Suite 201, Dover, Delaware, USA
Phone:
Fax:
Website: https://www.lunglifeai.com/
Email:

Listings

ISIN: USU5500L1045
Sector: Pharma and Biotech, Pharma and Biotech
Main Indices: FTSE AIM All-Share